Description: Both LDTI and IFRS 17 have introduced numerous new metrics with most companies having only crossed the finish line, just complying with what's needed for reporting due the complexity and large amounts of data required to simply comply. How do you leverage all the work you did to get proper business insights across the organization that tie back to these reporting metrics?

Description: A panel of leading reinsurance executives will provide an overview of the health reinsurance market that explores existing reinsurance transactions reported under Schedule S, large claim research drawing insight from the latest five-year Merative Commercial MarketScan Research Database, stop-loss reinsurance options for Accountable Care Organizations (ACOs), and other reinsurance applications being seen in the market.

Description: Hear about the new hope biosimilars bring in helping payers and patients manage the rapidly growing pharmacy spend. The Big Event, encompassing multiple Humira biosimilars, launches in 2023 and could set the tone for how much biosimilars can be expected to contribute to solving our pharmacy spend challenges. What will be the financial impact of the Big Event and this coming wave? What can be done to maximize adoption of biosimilars? What strategies are available to maximize savings for payers and patients?

Description: At the conclusion of the first part, attendees will be able to describe sources of reserve redundancy for products under Principle Based Reserve (PBR) and products under Commissioners' Annuity Reserve Valuation Method (CARVM). Such products include Term Life, Whole Life, Universal Life, and Fixed Annuity with and without rider. We will also review sources of capital redundancy from the C-1 factor under Risk-Based Capital (RBC) and assets such as Unrated Asset Credit Fund can have high C-1 factor even if its risks are limited. At the conclusion of the second part, the attendees will learn about potential Reserve Relief reinsurance solutions. Such solutions can provide Reserve Relief for annuity and term life businesses, as well as potential innovative asset-side solutions. Asset managers can structure assets that the C-1 factor aligned with the corresponding risk.

Description: Renal disease is a very heterogenous medical condition whose end state is dialysis, a recurring cost intensive medical condition. Dialysis cost is one of the major medical cost drivers in USA. Insufficient and improper care management in the early stages of CKD (chronic kidney disease) leads to early incidence of end stage renal disease (ESRD) among CKD patients which not only leads to high medical costs, but also reflects poor health quality.

Description: This webcast will explore hedge strategies that can take advantage of synergies with existing business, improve liquidity and collateral management, incorporate opportunistic design-making, and reflect a company’s appetite for certain risks where excess returns can be earned.

Description: In this webcast, the presenter will cover mental health in insurance products. Learn about the public’s increased interest in mental health and the ways insurers can meet this demand, how we can embed such offerings in insurance and how to successfully expand mental health coverage to those in need. The second speaker will cover how cancer and the simplified issue insurance market has evolved in Korea. In this session, the speaker will share the ease of selling / onboarding, thus allowing a greater penetration of products.

Description: Hot Topics in Setting Pension Return Assumptions is the third in a series, following Mathematics of Pension Return Assumption and Inflation, focusing on Effects, Forecasts, and Role in Pension Valuations. What time horizon is more appropriate for Capital Market Assumption (CMA) forecasts: mid-term or long-term time horizon, or a blend of both? How do we map the asset classes of a plan's own investment policy to the asset classes of investment forecasters' CMAs? If we use asset-smoothing for valuation assets, should we use market-driven expected returns or smoothed/average versions of them?

Description: Our understanding of the biology of aging is increasing rapidly, creating insight into how and why any organism is aging. Some of the mechanisms by which the process of aging occurs in mammals are sufficiently well understood that clinical trials targeting them in humans to improve later life health and longevity are now being undertaken. Translating results seen in mammals to humans has the potential to increase life expectancy far beyond what we have seen historically. Come explore the current state and outlook of research.

Description: "Demographic components of Future Potential Old-Age Support Ratios – Kirill Andreev, Ph.D., United Nations, Population Division, New York, Mila Andreeva, KAMA Consulting Effect of internal Migration on the Health of Taiwan’s Elderly People – Jack C. Yue, Ph.D., – National Chengchi University, Department of Statistics, Taipei, TaiwanPopulation Aging and Canada’s Social Contract: Covid-19 Catalyst for Change – Douglas Andrews, FSA, FCIA, Ph.D., Lori J. Curtis, Ph.D., – University of Waterloo"